Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $63 from $64 and keeps an Outperform rating on the shares. Following completion of the upsized $748M secondary offering, the firm is incorporating the raise into its estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Xenon Sets Date for 2026 Annual Shareholder Meeting
- Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
- Xenon Strengthens Balance Sheet With Major Equity Offering
- Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
- Xenon Raises $650 Million in Upsized U.S. Equity Offering